Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 2

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 2
---
53,262  
     143,442 

    NET LOSS 
     (1,487,100) 
     (2,806,973) 
     (3,248,958) 
     (5,378,414)

    OTHER COMPREHENSIVE (LOSS) INCOME 
     (4,000) 
     3,804  
     (9,244) 
     2,971 

    COMPREHENSIVE LOSS 
    $(1,491,100) 
    $(2,803,169) 
    $(3,258,202) 
    $(5,375,443)

    Basic and diluted loss per share attributable to common stockholders 
    $(3.74) 
    $(16.11) 
    $(10.65) 
    $(40.15)

    Weighted average number of common shares outstanding – basic and diluted 
     397,513  
     174,220  
     304,960  
     133,944 

The accompanying notes are an integral part
of these condensed consolidated financial statements.

 5 

AETHLON MEDICAL, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
EQUITY

For the Three and Six Months Ended September 30,
2025 and 2024

(Unaudited)

    COMMON STOCK  
    ADDITIONAL  PAID IN  
    ACCUMULATED  
    ACCUMULATED  COMPREHENSIVE  
    TOTAL 

    SHARES  
    AMOUNT  
    CAPITAL  
    DEFICIT  
    INCOME (LOSS)  
    EQUITY 
  
    BALANCE – MARCH 31, 2025 
     258,531  
    $259  
    $173,095,221  
    $(167,954,817) 
    $(17,133) 
    $5,123,530 
  
    Issuance of common shares upon vesting of restricted stock units and net stock option exercises 
     1,340  
     1  
     (5,358) 
     –  
     –  
     (5,357)
  
    Stock-based compensation expense 
     –  
     –  
     72,442  
     –